Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pentoxifylline Effect in Patients With Diabetic Nephropathy.(PENFOSIDINE STUDY) (PENFOSIDINE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03664414
Recruitment Status : Recruiting
First Posted : September 10, 2018
Last Update Posted : February 7, 2019
Sponsor:
Collaborators:
Centro de Investigación Biomédica de Michoacán.
Hospital General Regional N° 1 Instituto Mexicano del Seguro Social.
Hospital General de Zona N° 83 Instituto Mexicano del Seguro Social.
Coordinación Auxiliar Medica de Investigación en Salud. Delegación Michoacán.
Information provided by (Responsible Party):
Maria Eugenia Galván Plata, Coordinación de Investigación en Salud, Mexico

Brief Summary:

One of the purposes of the management of the patient with chronic kidney disease (CKD)is to slow the decline of renal function. The mechanisms by which the renal function declines involve inflammatory and fibrotic responses due in part by the effects of oxidative stress. Pentoxifylline (PTX)is a drug that stimulates adenosine receptors, and produces inhibition of phosphodiesterases, as well as being a dopaminergic modulator through D1 and D2 receptors. Its main effects are inhibition of the inflammatory state by decreasing serum levels of tumor necrosis factor alpha (TNF-ɒ) and monocyte chemo attractant protein 1 (MCP_1), which may slow down the decline of renal function. It also produces diminish of sympathetic activity, with the reduction of circulating levels of norepinephrine (NA), which may contribute to the reduction of glomerulosclerosis in diabetic patients. In the connective tissue increases the activity of the collagenases and decrease of collagen, fibronectin and glucosamine of the fibroblasts as well as inhibition of oxygen free radicals. Due to its antioxidant, anti-inflammatory and anti-fibrotic effects, PTX can result in an excellent therapeutic option for the prevention of CKD in DM2.

This work proposes the use of pentoxifylline as treatment CKD in DM2. Its application in patients with CKD will allow a therapeutic management with different targets, for its antioxidant, anti-inflammatory and antifibrotic effects that will be evaluated by means of fibrosis, inflammation and oxidative stress markers. The results will be of great importance in clinical practice, since they will justify the use of a new pharmacological tool, already known, with minimal adverse effects and low cost, accessible to all strata of the population since it is found as generic.


Condition or disease Intervention/treatment Phase
Chronic Kidney Disease stage3 and 4 Type 2 Diabetes Mellitus Drug: pentoxifylline Phase 4

Detailed Description:

Patients will be randomly selected from the outpatient family medicine clinics. Once included, patients will be randomly allocated (by a computer-generated randomization list) to a study or control group. Over a period of 2 years, patients of the study group will receive one PTX tablet (400 mg) orally three times a day (at dinner time), whereas controls will receive one cellulose identical tablet on the same schedule.

All patients will continue with their usual treatment prescribed by their family doctor. Monthly visits will be scheduled for clinical and biochemical evaluations. A blood sample will be taken at baseline and every six months up to 24 months, for measurement of complete blood count, urea, creatinine, glucose, albumin, lipids, electrolytes, liver function tests, serum total proteins, (will be measure by usual methods). In serum samples at 0, 6, 12, 18 and 24 months, high sensibility C reactive protein will be measured by nephelometry, Brain natriuretic peptide and Serum Cystatin C will be measured by ELISA. Glomerular filtration rate (GFR) will be calculated based in Cystatin C level Grubb's equations. Vitamin C will be measured by HPLC. A 24 h ambulatory blood pressure monitoring (24 h ABPM), M-mode and two-dimensional echocardiographic, and an analysis of body composition by bioelectrical impedance will be done at baseline 6, 12, 18 and 24 months. To investigate health-related quality of life the short-form 36 (SF-36) questionnaire will be applied. Treatment compliance will be recorded by counting tablets left in the container at the end of each monthly visit and by the Morinsky Green test.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 196 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: blinded,multicenter, randomized, pentoxifylline vs placebo controlled clinical trial. Time: two years after the enrollment of the last patient.
Masking: Double (Participant, Investigator)
Masking Description: Plaebo controlled
Primary Purpose: Treatment
Official Title: Pentoxifylline Effect on Renal Function, Oxidative Stress, Inflammation, and Fibrosis Markers, and Quality of Life in Patients With Diabetic Nephropathy
Actual Study Start Date : March 1, 2018
Estimated Primary Completion Date : July 30, 2019
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo group
Placebo group will receive 1 tablet of cellulose pill to mimic pentoxifylline tablets three times a day with meals, during the following two years.
Drug: pentoxifylline
Pentoxifylline or placebo will be prescribed three times a day with meals. All the participants will continue with the usual treatment. Time frame: two years
Other Name: Trental

Active Comparator: Pentoxifylline group
Pentoxifillyne or experimental group will receive 400 mg of pentoxifylline three times a day with meals, during the following two years.
Drug: pentoxifylline
Pentoxifylline or placebo will be prescribed three times a day with meals. All the participants will continue with the usual treatment. Time frame: two years
Other Name: Trental




Primary Outcome Measures :
  1. Change in the glomerular filtration rate [ Time Frame: The measurements will be done baseline and every six months up to 24 months. ]
    It will be measure as to duplicate serum creatinine levels from baseline (mg/dL), or to pass from a stage of chronic kidney disease to he next stage (GFR mL/min)


Secondary Outcome Measures :
  1. Change in oxidative stress marker. [ Time Frame: Change is assessed baseline, 6 months, 12 months, 18 months and 24 months. ]
    The change in vit C level from baseline (normal range 4-8.8mg/ L)

  2. Change in fibrosis markers. [ Time Frame: Change is assessed baseline, 6 months, 12 months, 18 months and 24 months. ]
    Change in Nt_ProBNP from the baseline (Normal values up to 381 pg/mL)

  3. Change in inflammation markers. [ Time Frame: Change is assessed baseline, 6 months, 12 months, 18 months and 24 months. ]
    To assess inflammation high sensitivity C reactive protein will be measured by nephelometry. (normal value < 5 mg/L

  4. Change in health-related quality of life [ Time Frame: The questionnaire will be applied baseline and every six months up to 24 months. ]
    This outcome will be measured by the SF 36 questionnaire, themaximun punctuation is 100, as greater punctuation a better quality of life



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. CKD
  2. Type 2 diabetes mellitus
  3. Microalbuminuria
  4. Proteinuria.
  5. Creatinine plasma clearance ˂ of 60 mL / min.

Exclusion criteria:

  1. History of psychiatric disorders,
  2. Immunosuppressants treatment
  3. Herbalism Treatment
  4. History of chronic alcoholism.
  5. Type 1 diabetes mellitus.
  6. Chronic obstructive pulmonary disease.
  7. Pulmonary fibrosis
  8. Heart failure
  9. HIV-AIDS.
  10. Liver cirrhosis.
  11. Chronic hepatitis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03664414


Contacts
Layout table for location contacts
Contact: Maria Eugenia Galván Plata, M. D +015556276900 ext 21230 eugenia.galvan@imss.gob.mx
Contact: Carla A Carla Martínez Castuera Gómez, MD +015556276900 ext 21218 carla.martinez@imss.gob.mx

Locations
Layout table for location information
Mexico
Cibimi - Hgz 83 Imss Recruiting
Morelia, Michoacán, Mexico, 58290
Contact: Oliva Mejía - Rodríguez, PhD    01 4431853008    oliva.mejia@imss.gob.mx   
Sponsors and Collaborators
Maria Eugenia Galván Plata
Centro de Investigación Biomédica de Michoacán.
Hospital General Regional N° 1 Instituto Mexicano del Seguro Social.
Hospital General de Zona N° 83 Instituto Mexicano del Seguro Social.
Coordinación Auxiliar Medica de Investigación en Salud. Delegación Michoacán.
Investigators
Layout table for investigator information
Principal Investigator: Oliva Mejía-Rodríguez, PhD CIBIMI IMSS

Layout table for additonal information
Responsible Party: Maria Eugenia Galván Plata, Coordinacion de Investigacion en Salud, México, Coordinación de Investigación en Salud, Mexico
ClinicalTrials.gov Identifier: NCT03664414     History of Changes
Other Study ID Numbers: CNIC-2015-785-065
First Posted: September 10, 2018    Key Record Dates
Last Update Posted: February 7, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The individual participant data for all primary and secondary outcome measures will be made available
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: Data will be available six months after the end of the study
Access Criteria: Data access request will be reviewed by the research institutional board.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Maria Eugenia Galván Plata, Coordinación de Investigación en Salud, Mexico:
oxidative stress
fibrosis
inflammation
quality of life

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Kidney Diseases
Diabetes Mellitus, Type 2
Renal Insufficiency, Chronic
Diabetic Nephropathies
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Urologic Diseases
Renal Insufficiency
Diabetes Complications
Pentoxifylline
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Radiation-Protective Agents
Protective Agents
Physiological Effects of Drugs
Vasodilator Agents
Free Radical Scavengers
Antioxidants